Merck & Co. and Pfizer signed separate pacts for preclinical drug candidates to treat schizophrenia.
Whitehouse Station, NJ and New York (Jan. 3 and 7)-Merck & Co. and Pfizer signed separate pacts for preclinical drug candidates to treat schizophrenia.
Merck signed an exclusive worldwide agreement with Addex Pharmaceuticals (Geneva), to develop ADX63365, a positive allosteric modulator (PAM) that targets the metabotropic glutamate receptor 5 (mGluR5), which is believed to be an important target for treating schizophrenia and other conditions. The deal also includes mGluR5 PAM backup compounds.
Allosteric modulators are an emerging class of small-molecule therapeutics and may offer more sophisticated ways to normalize biological signaling compared with classical orthosteric agonists or antagonist drugs, according to an Addex release.
Under the agreement, Addex will initially receive $22 million. The company is eligible to receive as much as $455 million in research, development, regulatory, and sales milestones for the first product developed for two indications, and $225 million for the second product developed in two indications. Addex will receive royalties on the sales of any products resulting from this collaboration. In addition, the company has an option to copromote the drugs in certain European Union countries and will participate in the joint oversight committee, led by Merck, for further development.
In December 2007, Addex formed a separate collaboration with an affiliate of Merck, Merck Sharp and Dohme Research, to discover and develop PAMs targeting mGLUR4 for treating Parkinson’s disease and other undisclosed indications.
Pfizer and Taisho team
Pfizer signed an agreement with
Taisho Pharmaceutical
(Tokyo) for a worldwide (excluding Japan) collaboration to research, develop, and commercialize TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in preclinical development. TS-032 is a metabotropic glutamate receptor. Pfizer will give Taisho an initial payment of $22 million. Under the agreement, Taisho grants exclusive development and commercialization rights outside Japan for TS-032 to Pfizer.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.